Accentia Biopharmaceuticals, Inc.
324 South Hyde Park Avenue
Suite 350
Tampa,
FL 33606
United States - Map
Phone: 813-864-2554
Fax: 813-258-6912
Web Site: http://www.accentia.net
| Index Membership: | N/A | | Sector: | N/A | | Industry: | N/A | | Full Time Employees: | 140 |
|
| Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology. It operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products. Its products, which are under Phase III clinical trials, include SinuNase for the treatment of chronic rhinosinusitis; BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma; and Revimmune for the treatment of multiple sclerosis, an autoimmune disease that affects the central nervous system, and various autoimmune diseases, including systemic lupus, myasthenia gravis, and aplastic anemia. This segment also provides various consulting services relating to biopharmaceutical product development; and engages in the production of custom biologic products and cell culture instruments and systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by third-party development partners. Its products comprise Respi-TANN, a prescription antitussive decongestant for temporary relief of cough and nasal congestion; SinuTest, a test used in connection with the diagnosis of chronic sinusitis; and Zinotic, a treatment of superficial infections of the external ear. The company was founded in 2002 and is headquartered in Tampa, Florida. On November 10, 2008, Accentia Biopharmaceuticals, Inc. along with its affiliates filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Middle District of Florida, Tampa. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Francis E. O'Donnell Jr.,
Chairman and Chief Exec. Officer |
N/A
| N/A | Mr. Samuel S. Duffey J.D.,
Pres and Gen. Counsel |
N/A
| N/A | Mr. Alan M. Pearce , 60
Chief Financial Officer, Principal Accounting Officer |
$
285.00K | N/A | Mr. James A. McNulty CPA,
Sec. and Treasurer |
$
159.00K | N/A | Dr. Stephane Allard M.D., 55
Director of Medical Affairs |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.63% Nasdaq 
0.03%
Profile
